The performance of remission criteria when patients with at least two visits in remission during the radiographic follow-up period are selected (patients did not have to be in remission at baseline, visits did not have to be consecutive)
| Remission criteria | Remission and no progression (%) | Not remission and no progression (%) | Sensitivity | Specificity | LR+ (95% CI) | Unadjusted OR (95% CI) |
|---|---|---|---|---|---|---|
| DAS28–CRP at ≥2 visits, n=139 | 73 | 57 | 0.31 | 0.82 | 1.8 (1.3 to 2.5) | 2.1 (1.4 to 3.2) p=0.001 |
| SDAI at ≥2 visits, n=44 | 86 | 59 | 0.12 | 0.97 | 4.0 (1.7 to 9.4) | 4.5 (1.9 to 10.8) p=0.001 |
| CDAI at ≥2 visits, n=41 | 85 | 59 | 0.11 | 0.97 | 3.7 (1.6 to 8.7) | 4.1 (1.7 to 9.8) p=0.002 |
| ACR/EULAR at ≥2 visits, n=41 | 83 | 59 | 0.10 | 0.97 | 3.1 (1.4 to 6.9) | 3.5 (1.5 to 7.7) p=0.004 |
| SJC 0 at ≥2 visits, n=102 | 81 | 56 | 0.26 | 0.91 | 2.8 (1.8 to 4.7) | 3.4 (2.0 to 5.8) p<0.001 |
Sensitivity, specificity, positive likelihood ratios and logistic regression models, all with absence of progression as the outcome (good radiographic outcome, change in TSS <1 unit/year).
ACR, American College of Rheumatology; CDAI, clinical disease activity index; DAS28–CRP, disease activity score based on 28 joint count and C-reactive protein; EULAR, European League Against Rheumatism; LR+, positive likelihood ratio; SDAI, simplified disease activity index; SJC, swollen joint count; TSS, van der Heijde modified Sharp score.